

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE

00 AUG 14 AM 11: 19

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Pharmaceutical Research & Manufacturers of America			
2. Address ☐ Check if different than previously reported 1100 15th Street, N.W., Suite 900 Washington DC 20005 USA			
3. Principal Place of Business (if different from line 2) City State/Zip (or Country)			
4. Contact Name Matthew B. Van Hook		Telephone (202) 835-3513	E-mail (optional) 31350-12
7. Client Name ☒ Self		5. Senate ID # 30654000	

TYPE OF REPORT 8. Year 2000 Midyear (January 1-June 30) ☒ OR Year End (July 1-December 31) ☐

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ >> Termination Date _____

11. No Lobbying Activity ☐

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this reporting period were:
Less than \$10,000 ☐	Less than \$10,000 ☐
\$10,000 or more ☐ >> \$ _____ Income (nearest \$20,000)	\$10,000 or more ☒ >> \$ <u>33,980,000.00</u> Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options. ☒ Method A. Reporting amounts using LDA definitions only ☐ Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code ☐ Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature _____ Date 8/10/00

Printed Name and Title Matthew B. Van Hook - Deputy General Counsel Page 1 of 12

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific Lobbying issues

S. 2536, Appropriations for the Department of Agriculture and Related Agencies, FDA Appropriations
H.R. 4461, Appropriations for the Department of Agriculture and Related Agencies, FDA Appropriations

17. House(s) of Congress and Federal agencies contacted.
Department of Health & Human Services
Food & Drug Administration
House of Representatives
Senate

☐ Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Bantham, Russel		No
Holmer, Alan F.		No
Van Hook, Matthew B.		No
Currie, Rodger	Majority Counsel, House Commerce Committee	No
Mohler, Dave T.		No
Stewart, Shelley		Yes
Rubin, Peter	Legislative Director for Rep. Jim McDermott	Yes

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature _____ Date 8/10/00

Printed Name and Title Matthew B. Van Hook - Deputy General Counsel

Page 2 of 12

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

Item	Description	Data
18a	Lobbyist Name	Jones, Rebecca
18b	Covered Official Position	Prof. Staff Member, Senate Special Ctee on Aging
18c	New Lobbyist	Yes
18a	Lobbyist Name	Lynch, Ann-Marie
18b	Covered Official Position	Staff Dir., House Ways & Means Health Subctee
18c	New Lobbyist	Yes
18a	Lobbyist Name	Christy, James
18b	Covered Official Position	
18c	New Lobbyist	Yes

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific lobbying issues

H.R. 626, Health Care Research and Development and Taxpayer Protection Act, Oppose imposition of a counterproductive "reasonable pricing clause" on NIH patent licenses

S. 2536, Appropriations for the Department of Agriculture and Related Agencies, including FDA, Oppose amendments to extend patent restoration under the Hatch-Waxman Act to products that do not require FDA approval prior to marketing.

H.R. 4461, Appropriations for the Department of Agriculture and Related Agencies, including FDA, Oppose amendments to extend patent restoration under the Hatch-Waxman Act to products that do not require FDA approval prior to marketing.

S. 1172, Drug Patent Term Restoration Review Procedure Act of 1999, Limited to support for the concept of patent term restoration, except to also urge deletion of provisions different from H.R. 1598, which are unnecessary to the goals of H.R. 1598

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

House of Representatives

Patent and Trademark Office

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Buntham, Russel		No
Bello, Judith		No
Holmer, Alan F.		No
Van Hook, Matthew B.		No
Currie, Rodger	Majority Counsel, House Commerce Committee	No
Mohler, Dave T.		No
Rubin, Peter	Legislative Director for Rep. Jim McDermott	Yes

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____

Date 8/10/06

Printed Name and Title Matthew B. Van Hook - Deputy General Counsel

Page 4 of 12

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

Item	Description	Data
16	Lobbying Issues	H.R. 1598, Patent Fairness Act of 1999, Limited to support for the concept of patent term restoration
18a	Lobbyist Name	Jones, Rebecca
18b	Covered Official Position	Prof. Staff Member, Senate Special Ctee on Aging
18c	New Lobbyist	Yes
18a	Lobbyist Name	Christy, James
18b	Covered Official Position	
18c	New Lobbyist	Yes

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific Lobbying issues

S. 731, Prescription Drug Fairness Act of 1999,
H.R. 1885, International Prescription Drug Parity Act,
H.R. 2470, Medical Information Protection & Research Enhancement Act of 1999,
H.R. 2782, The Seniors Prescription Insurance Coverage Act of 1999,
H.R. 664, Prescription Drug Fairness Act of 1999,
S. 1191, International Prescription Drug Parity Act,
S. 578, Health Information Protection Act,
S. 2541, Medicare Expansion for Needed Drugs (MEND) Act of 2000,
S. 881, Medical Information Protection Act of 1999,
H.R. 3240, The Drug Import Fairness Act,
S. 2520, Medicine Equity and Drug Safety Act of 2000,

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

Department of Health & Human Services
Food & Drug Administration
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Bantham, Russel		No
Bello, Judith		No
Cole, Steven		No
Holmer, Alan F.		No
Lucas, William		No
Van Hook, Matthew B.		No
Currie, Rodger	Majority Counsel, House Commerce Committee	No

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature

Date 8/10/00

Printed Name and Title Matthew B. Van Hook - Deputy General Counsel

Page 6 of 12

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

Item	Description	Data
16	Lobbying Issues	S. 2464, Prescription Drug Fairness Act,
16	Lobbying Issues	S. 2466, (to require the U.S. Trade Representative to enter into negotiations to eliminate price controls imposed by certain foreign countries on prescription drugs),
16	Lobbying Issues	H.R. 4680, Medicare Rx 2000,
16	Lobbying Issues	S. 2807, Medicare Prescription Drug & Modernization Act,
16	Lobbying Issues	S. 2836, Medicare Rx Drug Discount and Security Act of 2000,
16	Lobbying Issues	S. 1480, The Seniors Prescription Insurance Coverage Equity Act of 1999.
16	Lobbying Issues	Executive Branch: FDA implementation of P.L. 105-115, the FDA Modernization Act of 1997

18a Lobbyist Name Mehler, Dave T.

18b Covered Official Position

18c New Lobbyist No

18a Lobbyist Name Stewart, Shelley

18b Covered Official Position

18c New Lobbyist Yes

18a Lobbyist Name Rubin, Peter

18b Covered Official Position Legislative Director for Rep. Jim McDermott

18c New Lobbyist Yes

18a Lobbyist Name Jones, Rebecca

18b Covered Official Position Prof. Staff Member, Senate Special Cttee on Aging

18c New Lobbyist Yes

18a Lobbyist Name Lynch, Ann-Marie

18b Covered Official Position Staff Dir., House Ways & Means Health Subcttee

18c New Lobbyist Yes

18a Lobbyist Name Guarducci, Mara

18b Covered Official Position Legislative Assistant, Rep. Jim Greenwood

18c New Lobbyist No

18a Lobbyist Name Christy, James

18b Covered Official Position

18c New Lobbyist Yes

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues

S. 2541, Medicare Expansion for Needed Drugs (MEND) Act of 2000,
S. 2836, Medicare Rx Drug Discount and Security Act of 2000,
S. 2807, Medicare Prescription Drug & Modernization Act,
H.R. 4680, Medicare Rx 2000,
S. 1895, Medicare Preservation and Improvement Act of 1999,
S. 1480, Seniors Prescription Insurance Coverage Equity Act of 1999,
S. 1204, Healthy Seniors Promotion Act of 1999,
H.R. 886, Medicare Prescription Drug Coverage Act of 1999,
H.R. 664, Prescription Drug Fairness for Seniors Act of 1999,
H.R. 2927, Affordable Prescription Drug Act,
H.R. 2375, Senior Prescription Drug Assistance Expansion Demonstration Act of 1999,

17. House(s) of Congress and Federal agencies contacted ☐ Check if None
Health Care Financing Administration, Dept. of Health and Human Services
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Bella, Judith</u>		<u>No</u>
<u>Cole, Steven</u>		<u>No</u>
<u>Hoimer, Alan F.</u>		<u>No</u>
<u>Lucas, William</u>		<u>No</u>
<u>Currie, Rodger</u>	<u>Majority Counsel, House Commerce Committee</u>	<u>No</u>
<u>Mohler, Dave T.</u>		<u>No</u>
<u>Stewart, Shelley</u>		<u>Yes</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature _____ Date 8/10/00

Printed Name and Title Matthew B. Van Hook - Deputy General Counsel Page 8 of 12

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

Item	Description	Data
16	Lobbying Issues	H.R. 2012, Medicare Prescription Drug Act of 1999,
16	Lobbying Issues	H.R. 1495, Access Medicare Prescription Drug Coverage Act of 1999,
16	Lobbying Issues	Executive Branch: Medicare reimbursement issues.
18a	Lobbyist Name	Rubin, Peter
18b	Covered Official Position	Legislative Director for Rep. Jim McDermott
18c	New Lobbyist	Yes
18a	Lobbyist Name	Jones, Rebecca
18b	Covered Official Position	Prof. Staff Member, Senate Special Ctee on Aging
18c	New Lobbyist	Yes
18a	Lobbyist Name	Lynch, Ann-Marie
18b	Covered Official Position	Staff Dir., House Ways & Means Health Subctee
18c	New Lobbyist	Yes
18a	Lobbyist Name	Guarducci, Mara
18b	Covered Official Position	Legislative Assistant, Rep. Jim Greenwood
18c	New Lobbyist	No
18a	Lobbyist Name	Christy, James
18b	Covered Official Position	
18c	New Lobbyist	Yes

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific Lobbying issues

H.R. 3665 and S. 2465, Prescription Price Equity Act,

H.R. 4686, Fair Balance Prescription Drug Advertising Act,

S. 1429, Taxpayer Refund Act of 1999,

H.R. 2488, Financial Freedom Act of 1999, re health care deductions

Department of the Treasury development of a Foreign Sales Corporation replacement proposal in response to a decision of the World Trade Organization.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Cole, Steven		No
Holmer, Alan F.		No
Currie, Rodger	Majority Counsel, House Commerce Committee	No
Rubin, Peter	Legislative Director for Rep. Jim McDermott	Yes
Jones, Rebecca	Prof. Staff Member, Senate Special Ctee on Aging	Yes
Guarducci, Mara	Legislative Assistant, Rep. Jim Greenwood	No
Christy, James		Yes

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature

Date 8/10/00

Printed Name and Title Matthew B. Van Hook - Deputy General Counsel

Page 10 of 12

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific Lobbying issues

H.R. 434, Africa Growth & Opportunity Act,

Congressional Matters:

FY 2001 Appropriations — Foreign Operations, Export Financing and Related Programs

Renewing Trade Negotiation Authority; Strengthening Protection of Intellectual Property

FY 2001 Appropriations — Commerce, Justice, State Department appropriations bill (re protecting intellectual property rights).

Executive Branch:

Strengthening protection of Intellectual property — accession of China to the WTO; South Africa

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

Department of Commerce

House of Representatives

Office of the United States Trade Representative

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Bello, Judith		No
Holmer, Alan F.		No
Lucas, William		No
Herzfeld, Shannon S.S.		No
Mohler, Dave T.		No
Rubin, Peter	Legislative Director for Rep. Jim McDermott	Yes
Christy, James		Yes

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature

Date 8/10/00

Printed Name and Title Matthew B. Van Hook - Deputy General Counsel

Page 11 of 12

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different from line 20)

City _____ State/Zip (or Country) _____

22. New general description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
Caldwell, Barry

ISSUE UPDATE

24. General lobbying issues previously reported that no longer pertain

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Business (city and state or country)

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

Name	Address	Principal Place of Business (city and state or country)	Amount of contribution for lobbying activities	Ownership % in client

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client, or affiliated organization

Signature Matthew B. Van Hook Date 8/18/00

Printed Name and Title Matthew B. Van Hook - Deputy General Counsel

Page 12 of 12